Unraveling Role of Tumor Suppressor in Gene Expression and Ovarian Tumorigenesis

July 5, 2018 6:21 pm

The tumor suppressor protein ARID1A controls global transcription in ovarian epithelial cells, according to new research conducted at The Wistar Institute, which provided mechanistic insight into tumorigenesis mediated by ARID1A loss in ovarian cancer. Study results were published online in

Read more

Endometriosis Not a Factor in Survival of Patients with Clear Cell Ovarian Cancer, Study Finds

July 5, 2018 6:11 pm

by Ana Pena

Endometriosis does not worsen or improve survival of patients with ovarian clear cell carcinoma, a study suggests.

Researchers found that for these patients, resistance to treatment with platinum-based chemotherapy is the most important predictor of poor outcome.… Read more

Can Anxiety and Early Life Adversity Affect Ovarian Cancer Outcomes?

June 27, 2018 6:21 pm

In women with a recent ovarian cancer diagnosis, decreased anxiety was found to be associated with better regulated cortisol profiles, according to a new study. Those with early life adversity and other factors associated with anxiety had sustained anxiety and … Read more

ASCO 2018: Dendritic Cell Vaccine

June 20, 2018 5:46 pm

Dendritic cell vaccine improved progression-free survival when administered sequentially after chemotherapy. The vaccine provides a promising maintenance treatment option to delay progression of epithelial ovarian carcinoma.

This outcome of an interim analysis of a phase II, open-label, randomized, multicenter trial … Read more

Bevacizumab Rechallenge Benefit in Recurrent Ovarian Cancer?

June 19, 2018 5:43 pm

A new study suggests that a rechallenge with bevacizumab in combination with platinum-based chemotherapy may prolong progression-free survival (PFS) in patients with recurrent ovarian cancer (ROC) who already received this agent during first-line treatment. The study was presented by Italian … Read more

My Stomach Pain Proved To Be Advanced Ovarian Cancer, and I Didn’t Like The Odds.

June 19, 2018 5:37 pm

By: Susan Lisovicz

I’m glad I was lying down when the doctor told me the true cause of my stomach pains.

“Well, you’ve got a tumor” were his first words to me. I had just awakened in a hospital bed … Read more

FDA Approves Bevacizumab Plus Chemotherapy in Advanced OC

June 14, 2018 7:32 pm

Today, the U.S. Food and Drug Administration (FDA) approved bevacizumab (Avastin) in combination with chemotherapy (carboplatin and paclitaxel) followed by bevacizumab as a single agent for the treatment of women with advanced (stage III or IV) ovarian cancer following initial … Read more

Clearity Presents Results at ASCO Conference

June 13, 2018 7:22 pm

Results from analysis of clinical and tumor profiling data from ovarian cancer patients in the Clearity Foundation Data Repository were presented in two studies at the recent ASCO conference that took place June 1-5 in Chicago, Ill.

The first study

Read more

Webinar: Understanding Immuno-Oncology for Ovarian Cancer

June 12, 2018 6:35 pm

Tuesday, June 19th at 6:00 pm EST

Join OCRFA and presenter Dr. Dmitriy Zamarin of Memorial Sloan Kettering Cancer Center, for a free live webinar on immuno-oncology, one of the most promising and fastest growing areas of cancer research and … Read more

FDA Clears Paxman Scalp-Cooling System

June 12, 2018 6:23 pm

The FDA granted expanded clearance to the Paxman Scalp Cooling System, allowing the device to be used by patients with any type of solid tumor.

The Paxman Scalp Cooling System (Paxman) — designed to reduce hair loss among patients who … Read more

ASCO Poster Rounds: Combo Tx Effective in Ovarian Cancer

June 11, 2018 7:55 pm

Combination of the investigational agent cediranib and olaparib (Lynparza) was active against ovarian cancers that were both platinum-sensitive and platinum therapy resistant, researchers said here.

In her poster presentation, Joyce Liu, MD, of Dana-Farber Cancer Institute/Harvard Medical School in Boston, … Read more

Olaparib Plus Vistusertib Promising in Early Trial

June 8, 2018 9:48 pm

The combination of the PARP inhibitor olaparib with an mTORC1/2 inhibitor known as vistusertib was tolerable and had promising activity across endometrial, ovarian, and triple-negative breast cancers, according to a phase I trial. Results of the trial (abstract 5504Read more

PFS Rises in Ovarian Cancer with Repeat Bevacizumab

June 8, 2018 9:47 pm

Women with advanced ovarian cancer previously treated with bevacizumab (Avastin) had a 3-month improvement in progression-free survival (PFS) when they received second-line therapy that included bevacizumab, European investigators reported.

Median PFS increased from 8.8 months with platinum-based chemotherapy to 11.8 … Read more

Pembrolizumab Monotherapy Shows Activity in Advanced Recurrent OC

June 7, 2018 9:52 pm

Pembrolizumab monotherapy is associated with antitumor activity in patients with advanced recurrent ovarian cancer, interim results from the phase 2 KEYNOTE-100 study suggest.

Notably, objective response rates among study subjects increased in tandem with increased programmed death-ligand 1 (PD-L1) expression, … Read more

Non-Chemo Combo Active in Ovarian Cancer

June 6, 2018 7:00 pm

The combination of two targeted agents – the PARP inhibitor niraparib (Zejula) plus the checkpoint inhibitor pembrolizumab (Keytruda) — appears to elicit a durable response among women with heavily pretreated, refractory ovarian cancer, researchers reported here.

About 25% of women … Read more

Report: Ovarian Cancer Rates Continue to Decrease

June 6, 2018 5:30 pm

A new report from the American Cancer Society finds rates of ovarian cancer have declined by 29% between 1985 and 2014. Ovarian cancer deaths have declined 33% between 1976 and 2015. The report, Ovarian Cancer Statistics, 2018, was published … Read more

Quality Of Life Is The Name Of The Game

June 4, 2018 9:01 pm

By: Annette McElhiney

I will never forget in 2008 when my doctor told me, “you have ovarian cancer.” Few words in the English language provoke a stronger reaction of fear and dread than the word cancer. However, there are … Read more

Is Adjuvant Chemo Warranted In Stage I Ovarian Clear Cell Carcinoma?

May 31, 2018 7:11 pm

In patients with stage I ovarian clear cell carcinoma, the use of adjuvant chemotherapy was associated with superior overall survival (OS), according to results of a large, retrospective cohort study.

The finding, published in Gynecologic Oncology, provides further evidence … Read more

Multi-epitope T-cell Vaccine Shows Promise in Ovarian, Breast Cancer

May 29, 2018 7:07 pm

Clinicians in the not-too-distant future may have something new to offer women with breast cancer and ovarian cancer in whom initial therapy fails to yield a response. Writing in Clinical Cancer Research, investigators at the Mayo Clinic report that … Read more

Fully Reprogrammed Virus Offers New Hope As Cancer Treatment

May 25, 2018 7:04 pm

A cancer treatment that can completely destroy cancer cells without affecting healthy cells could soon be a possibility, thanks to research led by Cardiff University.

The team of researchers has successfully ‘trained’ a respiratory virus to recognise ovarian cancer and … Read more